Highlights

Market size:

(1) VIIBRYD (Vilazodone Hydrochloride) is common treatment for Major depressive disorder (MDD), approval in 2011, after that, the sales of VIIBRYD reached 559 million USD and 60 million tablets in US market in 2021.

(2) However, Patients with depression usually have clinical symptoms of loss of appetite, and strict medication methods affect the therapeutic effect of drugs and the compliance of patients (In the clinical trials of VIIBRYD, there were cases of patients who were delayed in taking medication due to refusal to eat)

Modified Vilazodone

(1) By using polymer material technology, the API molecules are loaded in water-soluble polymer material cavity to achieve the solubilization effect.

(2) When it reaches the absorption site, the released API is absorbed.

(3) The proportion of API absorbed into the blood is higher, the bioavailability is higher, and it is not affected by food and other factors.

(4) Compared with VIIBRYD, the bioavailability of asset increased by 10 - 20%, the food effect is eliminated, and the used dosage is reduced.

Research Progress:

(1) BE study in US，estimate FDA approval date 2024